Glibenclamide and cardio-metabolic risk: A systematic review

International Journal of Diabetes in Developing Countries

Volumn 34, Issue 2, 2014, Pages 61-68

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cardio metabolic risk; Glibenclamide; Glycemic control; Hypoglycemia; Secretagogues

Indexed keywords

EID: 84904185632     PISSN: 09733930     EISSN: 19983832     Source Type: Journal    
DOI: 10.1007/s13410-014-0205-z     Document Type: Review

References (34)

1. Holman RR, Paul SK, Bethel MA, Matthews DR. Neil HA.10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
2. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35:S11-63.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
4. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 2004;64:1339-58.
5. Derosa G. Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus. Drugs Ther Perspect. 2006;22:1-6.
6. Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, et al. Are sulphonylureas all the same? a cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007;23:479-84.
7. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006;22:477-82.
8. Mannucci E, Monami M, Masotti G, Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev. 2004;20:44-7.
9. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309:1286-91.
10. Maffioli P, Derosa G. Hypoglycemia, its implications in clinical practice, and possible ways to prevent it. Curr Med Res Opin. 2014;30(5):771 - 3.
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of randomized controlled trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
12. Skoff RA, Waterbury NV, Shaw RF, Egge JA, Cantrell M. Glycemic control and hypoglycemia in veterans health administration patients converted from glyburide to glipizide. JMCP. 2011;17:664-71.
13. Inukaia K, Watanabe M, Nakashima Y, Sawac T, Takata N, Tanaka M, et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Res Clin Pract. 2005;68:250-7.
14. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care. 2005;28:2093-99.
15. Garber AJ, Donovan DS, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3598-604.
16. Dailey 3rd GE, Mohideen P, Fiedorek FT. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. Clin Ther. 2002;24:1426-38.
17. UKPDS. study group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UKPDS. 1998;352:837-53.
18. Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, et al. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. Diabetes Technol Ther. 2013;15:214-22.
19. Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, et al. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy. Diabet Med. 2013;30:846-54.
20. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010;12:233-40.
21. Maffioli P, Fogari E, D'Angelo A, Perrone T, Derosa G. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. Eur J Gastroenterol Hepatol. 2013;25:1113-22.
22. Derosa G, Cicero AF, Fogari E, D'Angelo A, Bianchi L, Maffioli P. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Horm Metab Res. 2011;43:505-12.
23. Draeger KE, Wernicke-Panten K, Lomp HJ, Schüler E, Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res. 1996;28:419-25.
24. Jørgensen CH, Gislason GH, Bretler D, Sørensen R, Norgaard ML, Hansen ML, et al. Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction-a nationwide study. Int J Cardiol. 2011;152:327-31.
25. Jørgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention-a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54.
26. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract. 2009;86:247-53.
27. Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, et al. Simon T; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators. impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95:4993-5002.
28. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900-8.
29. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43.
30. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-81.
31. O'Rourke B. Evidence for mitochondrial K + channels and their role in cardioprotection. Circ Res. 2004;94:420-32.
32. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K (ATP) channels. Diabetes. 1998;47:1412-8.
33. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386-99.
34. Holstein A, Hammer C, Hahn M, Kulamadayil NS, Kovacs P. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatrics patients. Expert Opin Drug Saf. 2010;9:675-81.